{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:27:04Z","timestamp":1790202424113,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V037633\/1"],"award-info":[{"award-number":["MR\/V037633\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtha.2024.03.027","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T11:37:48Z","timestamp":1714736268000},"page":"2156-2170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Dilemmas in the diagnosis and management of antiphospholipid syndrome"],"prefix":"10.1016","volume":"22","author":[{"given":"James E.","family":"Manning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa J.","family":"Arachchillage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.03.027_bib1","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2024.03.027_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-022-02726-9","article-title":"Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study","volume":"24","author":"Gu\u00e9don","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jtha.2024.03.027_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jtha.2024.03.027_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.18239","article-title":"Thrombophilia testing: A British Society for Haematology guideline","volume":"198","author":"Arachchillage","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.03.027_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.03.027_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16308","article-title":"2012 (Br. J. Haematol. 2012; 157: 47\u201358): use of direct acting oral anticoagulants","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.03.027_bib8","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.027_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.027_bib10","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jtha.2024.03.027_bib11","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study","volume":"50","author":"Ruffatti","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2024.03.027_bib12","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-3175-1","article-title":"Classification criteria for the antiphospholipid syndrome: not the same as diagnostic criteria for antiphospholipid syndrome","author":"Favaloro","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib13","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1515\/cclm-2021-0692","article-title":"Anti-phosphatidyl-serine\/prothrombin antibodies (aPS\/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?","volume":"59","author":"Tonello","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2024.03.027_bib14","article-title":"Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: diagnostic value added","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.03.027_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinbiochem.2022.12.007","article-title":"Anti-phosphatidylserine\/prothrombin complex antibodies (aPS\/PT) increase the risk for thrombosis based on lupus anticoagulant positivity","volume":"112","author":"Zhang","year":"2023","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jtha.2024.03.027_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2009.09.001","article-title":"Lupus anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?","volume":"125","author":"Schouwers","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.03.027_bib17","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.mbc.0000061283.28953.39","article-title":"The ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants","volume":"14","author":"Moore","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2024.03.027_bib19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/rth2.12472","article-title":"DOAC-Stop in lupus anticoagulant testing: direct oral anticoagulant interference removed in most samples","volume":"5","author":"Baker","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ajcp\/aqab149","article-title":"Performance characteristics of DOAC-Remove for neutralization of the effects of apixaban and rivaroxaban in lupus anticoagulant assays","volume":"157","author":"Skaugen","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2024.03.027_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MBC.0000000000001214","article-title":"Direct oral anticoagulant adsorption and laboratory detection of lupus anticoagulant","volume":"34","author":"Novelli","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2024.03.027_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1515\/cclm-2019-1240","article-title":"Mixing studies for lupus anticoagulant: mostly yes, sometimes no","volume":"58","author":"Favaloro","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2024.03.027_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/rth2.12245","article-title":"Ruling out lupus anticoagulants with mixing test\u2013specific cutoff assessment and the index of circulating anticoagulant","volume":"3","author":"Kumano","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib24","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Tripodi","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.15585","article-title":"Semiquantitative interpretation of anticardiolipin and anti\u03b22glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib26","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1600-0412.2011.01236.x","article-title":"High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome","volume":"90","author":"Simchen","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jtha.2024.03.027_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0037-1613606","article-title":"Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies","volume":"90","author":"Neville","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","author":"Ruffatti","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2024.03.027_bib29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib30","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jth.13379","article-title":"IgG\/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis","volume":"14","author":"Kelchtermans","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib31","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.027_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jth.14633","article-title":"The (non-)sense of detecting anti-cardiolipin and anti-\u03b22glycoprotein I IgM antibodies in the antiphospholipid syndrome","volume":"18","author":"Chayoua","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib33","first-page":"1560","article-title":"Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals","volume":"31","author":"Gir\u00f3n-Gonz\u00e1lez","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jtha.2024.03.027_bib34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0038-1648840","article-title":"Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects","volume":"72","author":"Vila","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib35","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.027_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0961203316657433","article-title":"Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity","volume":"26","author":"Yelnik","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.jtha.2024.03.027_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2024.03.027_bib38","article-title":"Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies","volume":"7","author":"Bala","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtha.2024.03.027_bib39","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2024.03.027_bib40","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.03.027_bib41","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.027_bib42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.03.027_bib43","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.027_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.03.027_bib45","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A\u00a0comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.027_bib46","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A\u00a0randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib50","first-page":"15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2009","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jtha.2024.03.027_bib51","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.027_bib52","article-title":"Antithrombotic therapy in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis","volume":"10","author":"Attachaipanich","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2024.03.027_bib53","article-title":"Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome","volume":"10","author":"Bala","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtha.2024.03.027_bib54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.16431","article-title":"What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.03.027_bib56","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/ijms24021331","article-title":"Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome","volume":"24","author":"Arachchillage","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2024.03.027_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"Nuri","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.jtha.2024.03.027_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2024.03.027_bib59","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib62","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.55563\/clinexprheumatol\/cc5taf","article-title":"Rituximab for refractory manifestations of the antiphospholipid syndrome: a multicentre Israeli experience","volume":"39","author":"Agmon-Levin","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jtha.2024.03.027_bib63","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A\u00a0pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jtha.2024.03.027_bib64","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2024.03.027_bib65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00277-005-0028-6","article-title":"Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab\u2014monitoring of antiphospholipid and anti-GP antibodies: a case report","volume":"85","author":"Trappe","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2024.03.027_bib66","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1055\/s-0043-1770784","article-title":"The effect of rituximab on antiphospholipid titers in patients with antiphospholipid syndrome","volume":"7","author":"Youkhana","year":"2023","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2024.03.027_bib67","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1177\/09612033221122147","article-title":"The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome","volume":"31","author":"Sayar","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.jtha.2024.03.027_bib68","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/ard.2010.134817","article-title":"Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression","volume":"70","author":"Agmon-Levin","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2024.03.027_bib69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.027_bib70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jtha.2024.03.027_bib71","first-page":"18","article-title":"Influence of statin therapy on antiphospholipid antibodies and endothelial dysfunction in young patients with coronary artery disease and systemic lupus erythematosus","volume":"18","author":"Mazurek","year":"2020","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jtha.2024.03.027_bib72","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/rheumatology\/keab410","article-title":"Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome","volume":"61","author":"Kwon","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2024.03.027_bib73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2022-166074","article-title":"Anticoagulation practice, recurrent thrombosis, and major bleeding in antiphospholipid syndrome \u2013 a multicentre observational study in the United Kingdom","volume":"140","author":"Crossette-Thambiah","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.027_bib74","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.thromres.2015.03.030","article-title":"Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome","volume":"135","author":"Efthymiou","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.03.027_bib75","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MBC.0b013e32833581a3","article-title":"Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients","volume":"21","author":"Rosborough","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2024.03.027_bib76","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jtha.2024.03.027_bib77","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0037-1613033","article-title":"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies","volume":"87","author":"Espinola","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib78","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.027_bib79","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.027_bib80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/RHU.0000000000000409","article-title":"Stents coated with mammalian target of rapamycin inhibitors (mTOR) appear to be the best choice in patients with antiphospholipid syndrome and myocardial infarction","volume":"22","author":"Mora-Ram\u00edrez","year":"2016","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.jtha.2024.03.027_bib81","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.42459","article-title":"Fluctuation of anti-domain 1 and anti-\u03b22 -glycoprotein I antibody titers over time in patients with persistently positive antiphospholipid antibodies","volume":"75","author":"Chighizola","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jtha.2024.03.027_bib82","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ard.48.12.1023","article-title":"Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study","volume":"48","author":"Out","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2024.03.027_bib83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH14-05-0416","article-title":"Diagnosis and management of non-criteria obstetric antiphospholipid syndrome","volume":"113","author":"Arachchillage","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.027_bib84","first-page":"557","article-title":"High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population","volume":"69","author":"Manoussakis","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtha.2024.03.027_bib85","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.exger.2004.08.003","article-title":"Anti-beta 2 glycoprotein I antibodies in centenarians","volume":"39","author":"Meroni","year":"2004","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jtha.2024.03.027_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry.\u201d","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2024.03.027_bib87","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/hematology.2019000043","article-title":"What\u2019s new in obstetric antiphospholipid syndrome","volume":"2019","author":"Branch","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2024.03.027_bib88","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","article-title":"Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone","volume":"174","author":"Kutteh","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2024.03.027_bib89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.03.027_bib90","first-page":"CR132","article-title":"The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies","volume":"12","author":"Goel","year":"2006","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jtha.2024.03.027_bib91","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00404-011-2055-y","article-title":"Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome","volume":"285","author":"Alalaf","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jtha.2024.03.027_bib92","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00006250-200212000-00032","article-title":"Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment","volume":"100","author":"Farquharson","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jtha.2024.03.027_bib93","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.080763","article-title":"Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial","volume":"36","author":"Laskin","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jtha.2024.03.027_bib94","doi-asserted-by":"crossref","first-page":"525.e1","DOI":"10.1016\/j.ajog.2017.01.026","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2024.03.027_bib95","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2024.03.027_bib96","doi-asserted-by":"crossref","first-page":"273.e1","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2024.03.027_bib97","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.autrev.2015.04.010","article-title":"Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?","volume":"14","author":"De Carolis","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2024.03.027_bib98","doi-asserted-by":"crossref","first-page":"290.e1","DOI":"10.1016\/j.ajog.2020.09.007","article-title":"Hydroxychloroquine early in pregnancy and risk of birth defects","volume":"224","author":"Huybrechts","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2024.03.027_bib99","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1093\/rheumatology\/kead384","article-title":"British Society of Rheumatology guideline working group response to European Medicines Agency safety update on hydroxychloroquine","volume":"63","author":"Russell","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2024.03.027_bib100","year":"2018","journal-title":"HYPATIA study"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T22:06:00Z","timestamp":1721685960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362400240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":95,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S153878362400240X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.03.027","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dilemmas in the diagnosis and management of antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}